Kobo Biotech Ltd

As of June 30, 2024, Kobo Biotech Ltd carries a market capitalization of 90.54M, placing it among publicly traded companies globally. Its enterprise value stands at 90.54M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2024, Kobo Biotech Ltd has 23.83M shares outstanding.

These figures cover the twelve months ended June 30, 2024. The company generates approximately - - in revenue per employee across its workforce of 411.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Kobo Biotech Ltd's stock has gained approximately 45.74% over the past 52 weeks. The 50-day moving average sits at 4.65, while the 200-day moving average is 4.33.

Over the twelve months ended June 30, 2024, Kobo Biotech Ltd generated - - in revenue and converted that into -50.33M in net income, yielding earnings per share of -2.12. EBITDA reached -9.41M, while operating income came in at -50.11M.